Li Shu-Wen, Chiu Allen W, Huang Andy C, Lai Yu-Wei, Leu Jyh-Der, Hsiao Yi-Chun, Chen Shiou-Sheng, Hsueh Thomas Y
Division of Urology, Department of Surgery, Taipei City Hospital renai Branch, Taipei, Taiwan.
Department of Urology, School of Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.
Front Surg. 2022 Jul 29;9:966025. doi: 10.3389/fsurg.2022.966025. eCollection 2022.
Since there was no consensus on treatment options for localized prostate cancer, we performed a retrospective study to compare the long-term survival benefit of radiotherapy (RT) versus laparoscopic radical prostatectomy (LRP) in Taiwan.
218 patients with clinically localized prostate cancer treated between 2008 and 2017 (64 with LRP and 154 with RT) were enrolled in this study. The outcomes of RT and LRP were assessed after patients were stratified according to Gleason score, stage, and risk group. Crude survival, prostate cancer-specific survival, and metastasis-free survival were evaluated using the log-rank test.
The 5-year crude survival rate was 93.3% in the LRP group and 59.3% in the RT group. A significant survival benefit was found in the LRP group compared with the RT group ( = 0.004). Furthermore, significant differences were found in disease-specific survival (93.3% vs. 64.7%, = 0.022) and metastasis-free survival (48% vs. 40.2%, = 0.045) between the LRP and RT groups.
Men with localized prostate cancer treated initially with LRP had a lower risk of prostate cancer-specific death and metastases compared with those treated with RT.
由于对于局限性前列腺癌的治疗方案尚无共识，我们开展了一项回顾性研究，以比较台湾地区放射治疗（RT）与腹腔镜根治性前列腺切除术（LRP）的长期生存获益。
本研究纳入了2008年至2017年间接受治疗的218例临床局限性前列腺癌患者（64例行LRP，154例行RT）。根据Gleason评分、分期和风险组对患者进行分层后，评估RT和LRP的治疗结果。使用对数秩检验评估总生存率、前列腺癌特异性生存率和无转移生存率。
LRP组的5年总生存率为93.3%，RT组为59.3%。与RT组相比，LRP组有显著的生存获益（P = 0.004）。此外，LRP组和RT组在疾病特异性生存率（93.3%对64.7%，P = 0.022）和无转移生存率（48%对4 = 0.045）方面存在显著差异。
与接受RT治疗的男性相比，初始接受LRP治疗的局限性前列腺癌男性发生前列腺癌特异性死亡和转移的风险较低。
